You are here

bladder cancer

miR Scientific Presents Urine Based Test for Detecting Prostate and Bladder Cancer

miR Scientific Presents Urine Based Test for Detecting Prostate and Bladder Cancer

CP Wire

prostate cancer

Flag link:

miR Scientific Presents Urine Based Test for Detecting Prostate and Bladder Cancer

prostate cancer

Flag link:

Merck limits orders for bladder cancer drug as demand outstrips supply

Merck limits orders for bladder cancer drug as demand outstrips supply

Fierce Pharma

Flag link:

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

Bladder cancer readout sees Nektar shares hit

Bladder cancer readout sees Nektar shares hit

Fierce Biotech

Nektar Therapeutics

Bristol-Myers Squibb

Flag link:

Theralase AnnouncesTwo Patients Free of Bladder Cancer After Single Treatment in Ph Ib Study

Theralase AnnouncesTwo Patients Free of Bladder Cancer After Single Treatment in Ph Ib Study

CP Wire

Flag link:

Theralase AnnouncesTwo Patients Free of Bladder Cancer After Single Treatment in Ph Ib Study

Flag link:

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

Biopharma Dive

Flag link:

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

Biopharma Dive

clinical trials

Flag link:

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Fierce Pharma

Flag link:

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

Motley Fool

prostate cancer

Merkel cell carcinoma

metastatic non-small cell lung cancer

metastatic breast cancer

Flag link:

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

Fierce Pharma

PARP inhibitors

Flag link:

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

Endpoints

Bristol-Myers Squibb

cervical cancer

Flag link:

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Fierce Pharma

Flag link:

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

Fierce Pharma

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Has Merck Lucked Into A $10 Billion Drug?

Has Merck Lucked Into A $10 Billion Drug?

Forbes

non-small cell lung cancer

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Fierce Pharma

Flag link:

Pages